PATH | VRL
Menu

Country Specific Predictions of the Cost-Effectiveness of Malaria Vaccine RTS,S/AS01 in Endemic Africa

This article, published in Vaccine, examines the cost-effectiveness and impact of malaria vaccine candidate RTS,S/AS01 in Africa. Using a variety of models of Plasmodium falciparum epidemiology, the study found that if RTS,S was implemented in 43 malaria-endemic countries, it has the potential to avert 123 million malaria episodes over the first 10 years. Assuming the price of the vaccine is US$5 per dose, the incremental cost-effectiveness ratio averages $188 per disability-adjusted life year averted across the 43 countries considered. The study goes on to identify key considerations for maximizing the impact of RTS,S, namely ensuring high coverage of the vaccine and mobilization of necessary resources.

Author: Galactionova K, Tediosi F, Camponovo F, Smith TA, Gething PW, Penny MA

Published: 2017

» Visit web page (English)

(Located at www.sciencedirect.com)

Citation: Galactionova K, Tediosi F, Camponovo F, Smith TA, Gething PW, Penny MA. Country Specific Predications of the Cost-Effectiveness of Malaria Vaccine RTS,S/AS01 in Endemic Africa. Vaccine. 2017;35(1):53-60.

Resource types: Peer-reviewed journal

Diseases/vaccines: Malaria

Topics: Immunization financing, Disease/vaccine specific information

Regions: Africa